Sanofi and Regeneron Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that a one-year Phase 3 study, known as LIBER…